Litcius/Paper detail

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

Philippe Merle, Jean‐Frédéric Blanc, Julien Edeline, Karine Le Malicot, Manon Allaire, Eric Assenat, Meriem Guarssifi, Mohamed Bouattour, Jean‐Marie Péron, Pierre Laurent‐Puig, Massimo Levrero, Charlotte Costentin, Boris Guiu, Harry Sokol, David Tougeron, Thomas Aparicio, Jean‐Charles Nault, Jean–Marc Phelip

2023Digestive and Liver Disease22 citationsDOIOpen Access PDF

Topics & Concepts

AtezolizumabMedicineBevacizumabInternal medicineOncologyHepatocellular carcinomaIpilimumabClinical endpointNivolumabGastroenterologyClinical trialCancerImmunotherapyChemotherapyHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesHepatitis C virus research
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial | Litcius